Drugs

Tovorafenib has now been approved for young patients with relapsed or progressive pediatric low-grade glioma – Dana-Farber Cancer Institute

Photo taken from Karen D. Wright/LinkedIn

Apr 28, 2024, 11:48

Tovorafenib has now been approved for young patients with relapsed or progressive pediatric low-grade glioma – Dana-Farber Cancer Institute

Dana-Farber Cancer Institute recently shared on LinkedIn:

“For more than a decade, a collaborative team of experts at Dana-Farber, with support from generous families, patient advocates, and the National Cancer Institute (NCI), carried out the scientific detective work that helped transform an orphaned drug into a medicine, tovorafenib, that has now been approved for young patients with relapsed or progressive pediatric low-grade glioma.

‘This is an example of what Dana-Farber is capable of. It’s a really nice example of just how much preclinical work goes into a discovery like this one. An approval for a pediatric tumor doesn’t happen very often. I think this Dana-Farber team can be very proud.’ – Karen D. Wright, MD.”

Source: Dana-Farber Cancer Institute/LinkedIn

brain tumors cancer cancer drugs Dana-Farber Cancer Institute Karen D. Wright low-grade glioma National Cancer Institute NCI OncoDaily Oncology pediatric low-grade glioma pediatric tumor tovorafenib

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage